Revolution Medicines is a global, commercial-stage oncology company dedicated to discovering, developing, and delivering innovative medicines for patients with RAS-addicted cancers. Leveraging its differentiated RAS(ON) tri-complex inhibitor platform, the company is advancing a broad, integrated portfolio of oral RAS(ON) inhibitors designed to directly target the active, cancer-driving state of RAS. Founded on rigorous scientific inquiry and a willingness to challenge long-held assumptions, Revolution Medicines is committed to changing the trajectory of disease for patients with RAS-addicted cancers worldwide. Our people are united by a shared way of working: follow the science, challenge assumptions, act with urgency, and hold ourselves to a high standard of rigor—all in service of patients. The Opportunity: The Director of Clinical Service Provider Contracting, Early Stage, will lead Service Provider sourcing, requests for information/proposal (RFIs/RFPs), contracting, and governance for assigned early-stage clinical programs. This role will partner with Clinical Operations and study teams to define service requirements and establish agreements that support first-in-human, dose-escalation, and dose-expansion studies. The Director will manage contracting priorities, negotiate commercial terms, and oversee Service Provider relationships in collaboration with Clinical Business Operations, Finance, Legal, Procurement, and Quality.
Stand Out From the Crowd
Upload your resume and get instant feedback on how well it matches this job.
Job Type
Full-time
Career Level
Director